Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 680
- Registration Number
- NCT06623422
- Locations
- 🇺🇸
Providence St. Jude Medical Center ( Site 0106), Fullerton, California, United States
🇺🇸Ellis Fischel Cancer Center ( Site 0133), Columbia, Missouri, United States
🇺🇸Lake Regional Hospital-Cancer Center ( Site 0123), Osage Beach, Missouri, United States
A Phase 1b Study of TTF in Combination With Durvalumab and GemCis in BTC.
- Conditions
- Biliary Tract Cancers (BTC)
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 60
- Registration Number
- NCT06611345
- Locations
- 🇨🇳
Anhui Provincial Hospital, He Fei, China
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal CancerAdvanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
- Conditions
- Metastatic Nonsmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 851
- Registration Number
- NCT06607393
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
- Conditions
- Non-Small Cell Lung CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06594874
- Locations
- 🇨🇳
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer
- Conditions
- Gallbladder Cancer Unresectable
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 33
- Registration Number
- NCT06591650
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 304
- Registration Number
- NCT06585189
A Study of Gemcitabine/Cisplatin Plus Cemiplimab (REGN2810, Anti-PD-1) With or Without Fianlimab (REGN3767, Anti-LAG-3) in Patients With Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
- Conditions
- Muscle-Invasive Bladder CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 36
- Registration Number
- NCT06571708
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT06564844
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1000
- Registration Number
- NCT06561386
- Locations
- 🇮🇹
Local Institution - 0222, Ravenna, Italy
🇺🇸Local Institution - 0368, Tucson, Arizona, United States
🇺🇸Local Institution - 0112, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.